+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 80 Actively Recruiting clinical trials

L

Actively Recruiting

This research evaluates the long-term safety and tolerability of LB-102 in adults with stable schizophrenia who are experiencing inadequate response or side effects from their current antipsychotic medications, or who have completed earlier LB-102 studies. It is a Phase 3, open-label, multicenter study focusing on patients who wish to change medications or continue treatment with LB-102. Participants receive LB-102 with flexible dosing ranging from 50 mg to 100 mg. The study is open-label, meaning all participants receive the study drug without a placebo comparison. The treatment period lasts 52 weeks, during which researchers monitor safety and tolerability. Throughout the study, participants are closely assessed for adverse events and treatment-emergent events to evaluate safety. Effectiveness is also measured using the Positive and Negative Syndrome Scale PANSS. The study duration is one year, during which participants undergo regular evaluations to track their response and monitor any side effects.

Age: 18Years - 65YearsAll GendersPhase 3
23 locations
O

Actively Recruiting

Researchers are evaluating the long-term safety, tolerability, and effectiveness of ML-007C-MA in adults with schizophrenia. This open-label Phase 2 study includes participants who have recently completed a previous related study or new participants enrolling directly. The study focuses on adults aged 18 to 65 diagnosed with schizophrenia who may benefit from ongoing pharmacotherapy and can maintain outpatient care. Participants will receive ML-007C-MA dosed at 2103 mg twice daily for up to 52 weeks. This single-group study does not involve placebo and assesses the medications impact over the treatment period. The study allows for continuous monitoring and adjustment based on the participants response and tolerability. During the study, participants will be involved in regular assessments to monitor safety and tolerability from the initial dose through the entire treatment period. Evaluations include clinical interviews, physical exams, ECGs, and laboratory tests to track any adverse effects or changes in health status. Researchers will also gather information from a reliable informant to support assessments. The total participation duration can be up to one year.

Age: 18Years - 65YearsAll GendersPhase 2
45 locations
C

Actively Recruiting

Researchers are evaluating the combination of pembrolizumab and sacituzumab govitecan-hziy compared to standard chemotherapy treatments for patients with advanced urothelial cancer that has spread locally or to other parts of the body. This phase III trial aims to compare survival rates and other treatment responses between the new combination therapy and the usual care involving drugs like carboplatin, cisplatin, gemcitabine, docetaxel, or paclitaxel. The study also examines quality of life and side effects for both approaches. Participants are randomly assigned to one of two groups. One group receives standard chemotherapy treatments such as carboplatin or cisplatin with gemcitabine, or alternatively docetaxel or paclitaxel, given intravenously in cycles every 21 days for up to six cycles if tolerated. The other group receives pembrolizumab intravenously on day 1 and sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle, continuing for up to 35 cycles or two years of pembrolizumab if there is no disease progression or unacceptable side effects. Throughout treatment, participants undergo blood tests and imaging scans like CT or MRI. Participants are followed closely during treatment with regular assessments including imaging and blood sample collection to monitor response and side effects. After treatment ends, follow-up visits occur at 30 days and then annually for five years to track overall survival and other health outcomes. The trial measures overall survival as the primary outcome and also evaluates progression-free survival, response rates, duration of response, adverse events, and quality of life aspects related to fatigue and bladder symptoms.

Age: 18Years +All GendersPhase 3
163 locations
S

Actively Recruiting

Researchers are evaluating the efficacy and safety of brenipatide, given alongside standard of care, compared with a placebo plus standard of care, in delaying the worsening of symptoms in adults with bipolar disorder. This phase 2, randomized, double-blind study aims to better understand how brenipatide might help manage bipolar disorder symptoms over time. Participants receive either one of two doses of brenipatide or a placebo, both administered by subcutaneous injection, combined with their standard bipolar disorder treatment. The study includes three main periods a screening period lasting about one month, a treatment period lasting at least six months, and a follow-up period of about two months. Study participation may be shortened if symptoms worsen or if the participant chooses to withdraw. During the study, participants are asked to self-inject the study medication, keep electronic and paper diaries, and complete questionnaires. Researchers will monitor outcomes such as time to relapse, changes in disability, depression and mania scores, quality of life, patient impressions, body weight changes, and treatment-related antibody development. Safety and effectiveness measures will be collected throughout treatment and follow-up, with total participation lasting around nine months or less depending on individual circumstances.

Age: 18Years - 75YearsAll GendersPhase 2
87 locations
P

Actively Recruiting

Researchers are evaluating brenipatide, a drug given as a subcutaneous injection, compared to a placebo to understand its effects and safety in adults with moderate-to-severe Alcohol Use Disorder AUD. The study is a Phase 3, multicenter, randomized, double-blind trial sponsored by Eli Lilly and Company. The trial aims to assess changes in drinking patterns over a period of up to 56 weeks. Participants receive escalating doses of the study drug or placebo administered by subcutaneous injection. The study includes two experimental periods with LY3537031 and a placebo group. Participants will self-inject the study intervention, keep diaries, and complete questionnaires throughout the trial. The trial design includes random assignment to one of the study groups, and treatment is monitored over the full 56 weeks. During the study, participants will attend regular visits to monitor their alcohol consumption using the Timeline Followback method, assess alcohol cravings with the Penn Alcohol Craving Scale, and evaluate health outcomes including body weight and quality of life measures. Researchers will also study the drugs pharmacokinetics and the presence of anti-drug antibodies. Participation lasts about 56 weeks, with ongoing safety and efficacy assessments throughout this period.

Age: 18Years - 75YearsAll GendersPhase 3
117 locations
E

Actively Recruiting

Researchers are evaluating the safety and tolerability of the investigational drug LTX-001 in adults aged 18 to 55 years who have schizophrenia experiencing a recent worsening of symptoms, known as an acute exacerbation. The study also aims to understand how the drug moves through the body pharmacokinetics, its early effects on schizophrenia symptoms, and changes in blood markers after taking LTX-001. Different dose levels of LTX-001 will be compared to a placebo to identify any differences in treatment effects. Eligible participants will stay in a research unit for about 35 nights, or up to 49 nights if a washout period from antipsychotic medications is needed, with three visits to the study site. During this time, they will receive oral doses of LTX-001 once or twice daily at specified amounts, or a placebo, under close monitoring. The study includes a follow-up visit one week after the overnight stay period. Participants will undergo a variety of assessments including medical history reviews, physical and neurological exams, heart electrical activity tests ECGs, blood and urine collections, and psychiatric evaluations using several standardized scales. Eye exams and brain wave recordings qEEG will also be conducted. Researchers will monitor safety through vital signs, neurological symptoms, suicidality risk, and other physical assessments from screening through day 42. The study will last about six weeks from screening to final follow-up.

Age: 18Years - 55YearsAll GendersPhase 1
10 locations
P

Actively Recruiting

Researchers are evaluating the safety and side effects of the drug PF-08046054SGN-PDL1V alone and in combination with pembrolizumab in participants with advanced solid tumors. These tumors are either metastatic, meaning they have spread through the body, or unresectable, meaning they cannot be removed by surgery. The study is a Phase 1 trial designed to find the best dose and assess safety and potential treatment effects in these cancers. The study has five parts Parts A and B focus on determining the appropriate dose of PF-08046054SGN-PDL1V. Part C uses the dose found to further evaluate safety and potential effectiveness of the drug alone. Parts D and E study the combination of PF-08046054SGN-PDL1V with pembrolizumab, given intravenously, to assess safety and possible benefits. Pembrolizumab is administered at 200 mg every three weeks. Participants will undergo assessments for side effects, laboratory abnormalities, and dose-limiting toxicities over about one month initially, with follow-up for up to three years to monitor longer-term outcomes like tumor response and survival. Safety monitoring includes tracking adverse events and immune responses to the drug. The study involves regular evaluations to measure tumor changes using standard criteria and to understand how the drugs behave in the body over time.

Age: 18Years +All GendersPhase 1
62 locations
R

Actively Recruiting

This research aims to evaluate the feasibility, safety, and tolerability of aticaprant as an additional treatment for adults with schizophrenia. The study focuses on stable participants receiving outpatient care and on a stable antipsychotic medication dose. It compares aticaprant with a placebo to understand how well participants can complete the study and assessments. Participants are randomly assigned to receive either aticaprant or a placebo during the double-blind treatment phase. The study includes monitoring for adverse events, vital signs, ECG, laboratory parameters, body weight, BMI changes, suicidality, and extrapyramidal symptoms. The treatment and observation period lasts up to 126 days with various assessment points. During the study, participants will undergo regular evaluations including safety checks, symptom assessments, and blood tests. Researchers will track completion rates of assessments and study milestones. Safety monitoring covers changes in vital signs, ECG, lab results, and mental health symptoms. The total participation time can be up to approximately four months.

Age: 18Years - 60YearsAll GendersPhase 1
8 locations
E

Actively Recruiting

Bipolar disorder is a serious and chronic mood condition affecting both adults and pediatric populations in the United States. This research aims to evaluate the safety and effectiveness of Icalcaprant in treating adults diagnosed with bipolar I or II disorder, focusing on depressive episodes. The study is a phase 2, randomized, placebo-controlled trial enrolling about 195 adults across approximately 35 sites. Participants will be randomly assigned to one of three groups two different doses of oral Icalcaprant or a matching placebo. They will take the assigned oral capsules once daily for six weeks. After the treatment period, there will be a four-week safety follow-up to monitor participants health. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, side effect monitoring, and questionnaires. The main outcomes measured include changes in depression severity using the Montgomery-sberg Depression Rating Scale and monitoring adverse events throughout the treatment and follow-up periods. This study is sponsored by AbbVie and aims to better understand treatment options for bipolar depression.

Age: 18Years - 65YearsAll GendersPhase 2
33 locations
R

Actively Recruiting

Schizophrenia is a serious psychiatric condition that affects thinking, language, perception, and self-awareness. Researchers are studying an investigational oral drug called emraclidine in adults with schizophrenia to assess its safety, how it moves through the body, and its effect on disease activity. This phase 2 trial involves about 268 participants across multiple sites in the United States. Participants are divided into two parts Part A and Part B. In Part A, participants receive oral emraclidine or placebo for either 14 days or up to 21 days depending on the dosing schedule, which may include a titration period. In Part B, participants receive oral emraclidine or placebo for 42 days. Following treatment, all participants enter a 30-day safety follow-up period to monitor any adverse effects. During the study, participants attend regular visits at hospitals or clinics for medical assessments, blood tests, and side effect monitoring. Researchers also collect questionnaire data to evaluate changes in symptoms. The trial measures adverse events and detailed drug levels in the blood, along with clinical scales assessing symptom severity and improvement. Total participation lasts up to approximately 74 days, including treatment and follow-up.

Age: 18Years - 65YearsAll GendersPhase 2
7 locations

1-10 of 80

1